ENTA vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical while ENTA counters with relative strength in Valuation, Options & Structure. Fundamentally, ENTA trades at 44.0x Forward P/E with -90.0% operating margin (-21.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTA Revenue | DMAC Revenue | ENTA Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $210M | $0M | 42.7% | -1352.2% | ENTA |
| FY2019 | $210M | N/A | 17.9% | N/A | ENTA |
| FY2020 | $120M | N/A | -34.0% | N/A | ENTA |
| FY2021 | $100M | N/A | -112.9% | N/A | ENTA |
| FY2022 | $90M | N/A | -143.7% | N/A | ENTA |
| FY2023 | $80M | N/A | -173.2% | N/A | ENTA |
| FY2024 | $70M | N/A | -179.9% | N/A | ENTA |
| FY2025 | $70M | N/A | -130.7% | N/A | ENTA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTA | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $326.2M | $503.1M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | 44.0x | N/M | Lower Multiple | ENTA |
| Forward P/E Ratio Valuation | 44.0x | N/M | Lower Multiple | ENTA |
| Revenue Growth (YoY) Growth | -21.6% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | -90.0% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | -96.9% | 0.0% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -70.1% | -114.6% | Higher ROE | ENTA |
| 52-Week Range Position Momentum | 10% ($10โ$17) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 0.89ฮฒ ยท 58% Vol | 1.72ฮฒ ยท 97% Vol | Lower Realized Risk | ENTA |
| Unified Institutional Score Composite Signal | 46.2 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | Tie |